Aditya Bardia, MD, MPH, FASCO, discusses how fam-trastuzumab deruxtecan-nxki compares with physician’s choice of chemotherapy in estrogen receptor-positive/HER2-low breast cancer.

The Toxicities and Adverse Effects That Emergency Physicians Must Know,” published in the December 2024 issue of Emeregency ...